Drug intelligence / Profile preview

HDM2006

Development stage: Phase 1
Lead developer: Hangzhou Zhongmei Huadong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HDM2006 is an orally bioavailable, small molecule inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), also known as MAP4K1. Developed by Hangzhou Zhongmei Huadong Pharmaceutical, HDM2006 is designed to target the negative regulatory role of HPK1 in immune cell signaling. HPK1 is a member of the MAP4K family that attenuates T-cell receptor (TCR) signaling; therefore, its inhibition is intended to enhance T-cell activation and anti-tumor immunity. The drug is currently being evaluated in Phase 1 clinical trials as a monotherapy for patients with advanced solid tumors to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)MAP4K1 (Hematopoietic progenitor kinase 1)

Beyond the preview

Go deeper on HDM2006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDM2006.

Explore the full profile